This company is a consumer-centred biotherapeutics business advancing a novel category of treatments for weight management and gut related chronic diseases. It combined with Capstar Special Purpose Acquisition Corp in January 2021.
Shareholders meeting today to vote on the business combination with weight loss maker Gelesis. The SPAC deal is anticipated to give Gelesis an equity value of around $1.3B.
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 (Plenity) for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.
Gelesis was founded by PureTech Ventures, a life sciences ventu...